Poor study design affects the entire clinical development process. From costly protocol amendments to excessive procedures, up-front design problems can delay study startup, hurt patient enrollment and retention, and continue to do harm throughout the execution of your trials. But, it doesn’t have to be this way.
Join Medidata for this complimentary webinar to learn:
- How optimized study design dramatically decreases excessive cost, waste and subject burden;
- The positive effect of streamlined protocols on downstream operational execution; and
- The benefits of a facilitated design and review process.
Jason Attanucci, Global Director, Study and Protocol Design, Medidata
Jason Attanucci is Global Director, Study and Protocol Design at Medidata. Jason began his career as an Immunologist with six years of research in immunotherapy and first in patient studies for the treatment of brain tumors at the University of Pittsburgh Cancer Institute. Throughout his career, Jason has held roles related to capture and use of data in basic, clinical and translational research. He has been involved with study and protocol design at Medidata for over four years and is passionate about clinical trial design.
Who Should Attend?
Senior level professionals working in the following areas:
- Biometrics / Statistics
- Clinical Operations
- Clinical Outsourcing
- Data Management
- Medical Writing
For pharmaceutical, biotechnology, medical device & diagnostic companies, academic research centers, CROs and other service providers
Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global Pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.